Labros Meimetis, Ph.D.
Assistant Professor of Radiology
- Postdoc, Harvard Medical School/MGH, Boston, MA, 2016
- Ph.D. University of British Columbia, Vancouver, Canada, 2012
- BSc. Simon Fraser University, Burnaby, Canada, 2006
- Meimetis, L.G.; Carlson, J.; Weissleder, R. “Bioorthogonal turn-on probes” US20160121002A1.
- Meimetis, L.G.; Nodwell, M.B.; Wang, X.; Andersen, R.J. “Decahydrobenzofluorene and dodecahydrofluorenoazepine derivatives as SHIP1 modulators and their preparation” US9000050B2.
- Please click here to see a full list of articles published by Dr. Meimetis on PubMed.
My research is focused on developing drugs and biologics to address escape pathways in tumors that result in current treatment strategies to fail in clinical trials and at best provide modest survival times in patients administered with approved drugs.
Therapies to overcome the following pain points will be developed:
- Heterogeneous tumors
- Poor solid tumor penetration using BiTE, bispecific and CAR-T therapies.
To enable novel drug discovery, we will perform research in the areas of:
- Eliciting tumor immunogenicity
- Adjuvants for enhanced immune cell penetration in solid tumors
- High potency warheads for antibody drug conjugates for low TAA copy number
Molecular imaging will play a key role in advancing these programs and will encompass Positron Emission Tomography (PET) using 18F, 89Zr, 68Ga and 44Sc labelled probes in preclinical animal models to determine immune cell distribution to identify the most suitable drug candidates to advance to the next round of testing.
Stony Brook Medicine
Department of Radiology
HSC Level 4, Room 092
Stony Brook, NY 11794-8460